Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Organon & Co.

Organon & Co. (OGN) Stock Overview

Explore Organon & Co.’s financial performance, market position, analyst ratings, and future outlook.

OGN●NYSE
HealthcareDrug Manufacturers - General
$13.62
$0.02(0.15%)
U.S. Market opens in 1h 34m

Organon & Co. (OGN)

Meyka AI Score

Z

Key Financials

Market Cap3.6B
P/E Ratio17.25
EPS (TTM)$3.35
ROE0.23%
Fundamental Analysis

AI Price Forecasts

1 Month$14.21
3 Months$16.93
1 Year Target$4.43

OGN Stock Analysis & Investment Overview (NYSE)

Our AI-powered analysis of Organon & Co. (NYSE: OGN) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Organon & Co.'s NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of OGN on the NYSE shows an RSI of 67.58, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $4.43 for the NYSE listing.

Key metrics behind Organon & Co.'s NYSE-traded stock include a P/E ratio of 17.25 and a market capitalization of 3.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of OGN on the NYSE.

Price Performance (NYSE: OGN)

1-Day Change
0.15%
5-Day Change
0.44%
1-Month Change
0.74%
3-Month Change
2.02%
6-Month Change
74.39%
Year-to-Date (YTD) Change
89.96%
1-Year Change
51.17%
3-Year Change
-42.31%
5-Year Change
-55.12%
All-Time (Max) Change
-59.04%

Contact Information

https://www.organon.com
551 430 6000
30 Hudson Street, Jersey City, NJ, 07302

Company Facts

100,000 Employees
IPO DateMay 14, 2021
CountryUS
Actively Trading

Frequently Asked Questions